カテゴリ： GlobalData, アメリカ, 企業調査

Cara Therapeutics Inc (CARA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cara Therapeutics Inc (CARA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7990
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：69
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruritus. Its lead product candidate includes KORSUVA injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, and dialysis of patients suffering from uremic pruritus. Cara Therapeutics develops molecules at novel analgesic and anti-inflammatory targets using proprietary drug screening technology. The company serves pharmaceutical and healthcare sectors. Cara Therapeutics is headquartered in Stamford, Connecticut, the US.

Cara Therapeutics Inc (CARA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Equity Offering 17
Cara Therapeutics Raises USD98.3 Million in Public Offering of Shares 17
Cara Therapeutics Raises USD92 Million in Public Offering of Shares 19
Cara Therapeutics Raises USD80.5 Million in Public Offering of Shares 21
Cara Therapeutics Raises USD0.1 Million in Private Placement of Shares 23
Cara Therapeutics Completes IPO For US$63.3 Million 24
Cara Therapeutics Inc – Key Competitors 26
Cara Therapeutics Inc – Key Employees 27
Cara Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 07, 2018: Cara Therapeutics Reports Second Quarter 2018 Financial Results 29
May 09, 2018: Cara Therapeutics Reports First Quarter 2018 Financial Results 31
Mar 15, 2018: Cara Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 33
Nov 02, 2017: Cara Therapeutics Reports Third Quarter 2017 Financial Results 36
Aug 03, 2017: Cara Therapeutics Reports Second Quarter 2017 Financial Results 38
May 04, 2017: Cara Therapeutics Reports First Quarter 2017 Financial Results 40
Mar 09, 2017: Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 42
Product News 44
10/17/2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017 44
08/01/2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer 45
06/27/2018: Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery 46
06/23/2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients 47
05/17/2017: Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics 48
05/14/2018: Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 49
05/12/2017: Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus 50
04/10/2018: Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation 51
03/28/2017: Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 52
Clinical Trials 54
Jul 19, 2018: Enteris BioPharmas Feasibility-to-Licensing Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA 54
Jul 11, 2018: Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients 55
Feb 28, 2018: Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA (CR845/difelikefalin) in Chronic Liver Disease Patients 56
Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus 57
Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting 58
Oct 31, 2017: Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 59
Oct 25, 2017: Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 60
Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 61
Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017 62
Oct 04, 2017: Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference 63
Aug 31, 2017: Cara Therapeutics to Participate in September Medical Meetings 64
Jul 12, 2017: Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease 65
Jun 29, 2017: Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee 66
Jun 21, 2017: Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment 67
Apr 24, 2017: Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Cara Therapeutics Raises USD98.3 Million in Public Offering of Shares 17
Cara Therapeutics Raises USD92 Million in Public Offering of Shares 19
Cara Therapeutics Raises USD80.5 Million in Public Offering of Shares 21
Cara Therapeutics Raises USD0.1 Million in Private Placement of Shares 23
Cara Therapeutics Completes IPO For US$63.3 Million 24
Cara Therapeutics Inc, Key Competitors 26
Cara Therapeutics Inc, Key Employees 27

List of Figures
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cara Therapeutics Inc (CARA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Yatra Online, Inc. (YTRA)：企業の財務・戦略的SWOT分析
    Yatra Online, Inc. (YTRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • IHI Aerospace Co Ltd：企業の戦略・SWOT・財務情報
    IHI Aerospace Co Ltd - Strategy, SWOT and Corporate Finance Report Summary IHI Aerospace Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Aequus Pharmaceuticals Inc (AQS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aequus Pharmaceuticals Inc (Aequus Pharmaceuticals) is a drug discovery and development company that develops differentiated drugs. The company’s pipeline products include AQS301, AQS302 and AQS303. Its commercial pipeline comprises ophthalmology products and transplant products. Aequus Phar …
  • Kone Corporation：企業の戦略・SWOT・財務分析
    Kone Corporation - Strategy, SWOT and Corporate Finance Report Summary Kone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Abiogen Pharma SpA：製薬・医療：M&Aディール及び事業提携情報
    Summary Abiogen Pharma SpA (Abiogen), a subsidiary of MDM Holding SpA, is a specialist pharmaceutical company, which develops, manufactures, and markets medicines with focus on musculo-skeletal health, and rare diseases. The company offers products in the form of oral solids, injectables, semi solid …
  • Petroleos de Venezuela SA-エネルギー分野：企業M&A・提携分析
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Intersurgical Ltd.：企業の戦略的SWOT分析
    Intersurgical Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • BRF SA：企業の戦略・SWOT・財務分析
    BRF SA - Strategy, SWOT and Corporate Finance Report Summary BRF SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Fiskars Corporation：企業の戦略・SWOT・財務情報
    Fiskars Corporation - Strategy, SWOT and Corporate Finance Report Summary Fiskars Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • CEL-SCI Corp (CVM)：企業の財務・戦略的SWOT分析
    CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Alliance Data Systems Corporation：企業の戦略・SWOT・財務情報
    Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Precision Optics Corporation Inc (PEYE)：医療機器：M&Aディール及び事業提携情報
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company provides custom optics solutions such as design and prototyping, f …
  • Dairy Farmers of America Inc：戦略・SWOT・企業財務分析
    Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report Summary Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Fortum Corporation：企業の戦略・SWOT・財務情報
    Fortum Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Enel Green Power SpA：企業の戦略的SWOT分析
    Enel Green Power SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Trex Company Inc (TREX)：企業の財務・戦略的SWOT分析
    Trex Company Inc (TREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Dilafor AB：製薬・医療：M&Aディール及び事業提携情報
    Summary Dilafor AB (Dilafor) is a drug development company that develops pharmaceutical products for obstetric indications. The company offers tafoxiparin, a proprietary heparan sulfate mimetic, which is used as an adjuvant therapy to promote cervical ripening and myometrial contractility. Its tafox …
  • Acuity Brands Inc (AYI)：電力：M&Aディール及び事業提携情報
    Summary Acuity Brands, Inc. (Acuity Brands) provides lighting and building management solutions and services. The company offers lighting solutions including devices such as luminaires, lighting controls, lighting components, power supplies, prismatic skylights, and integrated lighting systems. It a …
  • Trammo Inc.：戦略・SWOT・企業財務分析
    Trammo Inc. - Strategy, SWOT and Corporate Finance Report Summary Trammo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Saudi Arabian Mining Co：戦略・SWOT・企業財務分析
    Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report Summary Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆